噻托溴铵粉吸入剂对稳定期支气管扩张患者的临床疗效

Therapeutic effect of tiotropium bromide powder inhalation in patients with stable bronchiectasis

目的观察噻托溴铵对稳定期支气管扩张患者的临床疗效。方法将22例稳定期支气管扩张患者,予以噻托溴铵粉吸入剂18μg每日1次吸入治疗。于研究第1天、第28天检测1s用力呼气量(FEV1)、FEV1占预计值的百分比[FEV1(%)]、用力呼气量(FVC)、FEV1/FVC等指标及记录症状评分表,记录BODE指数。结果 22例患者使用噻托溴铵1月后FEV1%与使用前对照有所改善,但无统计学意义(t=-1.857,P>0.05);症状评分用药后1月与用药前比较降低,具有统计学意义(t=7.091,P<0.001);BODE指数用药后1月较用药前降低(t=2.982,P<0.05)。结论长期规律使用噻托溴铵粉吸入剂,能改善支气管扩张患者的临床症状,改善BODE指数,从而改善患者的运动耐量及生活质量。

Objective To observe the therapeutic effect of tiotropium bromide powder inhalation on stable bronchiectasis. Methods Twenty-two patients with stable bronchiectasis received inhalation of totropium bromide powder at the daily dose of 18 μg, and on days 1 and 28, the patients were examined for forced expiratory volume in one second （FEVl）, predicted value [FEVl （%）], forced expiratory volume （FEV）, and FEVl/FVC. The symptom score and BODE index were also recorded. Results After 1 month of inhalation therapy, the FEV1% of the patients showed a moderate increase but the increment was not statistically significant （t=-1.875, P0.05）; the symptom score and BODE index decreased significantly after the therapy （t= 7.091, P0.001; t=2.982, P0.05）. Conclusion Long-term inhalation of tiotropium bromide powder can improve the clinical symptoms and BODE index and enhance the exercise tolerance and quality of life of the patients with bronchiectasis.